🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Thyroid Gland Anaplastic Carcinoma

XL092 and Cemiplimab in BRAF WT Thyroid Cancer NCT06902376Phase 12 sites📍 Boston📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Cemiplimab, XL092 A Study of Avutometinib and Defactinib in People With Thyroid Cancer NCT06007924Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Avutometinib, Defactinib Sacituzumab govitEcan in THYroid Cancers NCT06235216Phase 211 sites📍 Barcelona📍 Ferrol📍 Hospitalet de Llobregat (Barcelona) Grupo Espanol de Tumores Neuroendocrinos · Tests: Sacituzumab govitecan DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. NCT05768178Phase 2, Phase 316 sites📍 Belfast📍 Birmingham📍 Bristol Cancer Research UK · Tests: Vemurafenib, Cobimetinib [177Lu]Lu-AKIR001 First-in-human Study NCT06639191EARLY Phase 11 site📍 Stockholm Karolinska University Hospital · Tests: [177Lu]Lu-AKIR001 DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. NCT07440290Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Dabrafenib, Trametinib NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) NCT06079333Phase 21 site📍 Leiden Leiden University Medical Center · Tests: dabrafenib/trametinib A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations NCT05503797Phase 270 sites📍 Beverly Hills📍 San Francisco📍 Westwood, Los Angeles Fore Biotherapeutics · Tests: Plixorafenib Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer NCT06374602Phase 21 site📍 Saint Petersburg Saint Petersburg State University, Russia · Tests: Pembrolizumab + Lenvatinib Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496Phase 1, Phase 23 sites📍 Gilbert📍 Tucson📍 Seattle University of Arizona · Tests: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer NCT07777536Phase 21 site📍 Shanghai Fudan University · Tests: Selective coverage radiotherapy, comprehensive coverage radiotherapy Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer NCT07068542NA1 site📍 Hangzhou Zhejiang Provincial People's Hospital · Tests: Sacituzumab Tirumotecan (SKB264) plus Tislelizumab, Sacituzumab Tirumotecan (SKB264)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy